| 新型肌松药拮抗剂sugammadex （ Org 25969）临床研究进展 |
| |
| 引用本文： | 周桥灵,;杨承祥.新型肌松药拮抗剂sugammadex （ Org 25969）临床研究进展[J].国外医学：麻醉学与复苏分册,2009(2):185-188. |
| |
| 作者姓名： | 周桥灵 ;杨承祥 |
| |
| 作者单位： | [1]徐州医学院江苏省麻醉医学研究所&江苏省麻醉学重点实验室, 221002; [2]中山大学附属佛山医院麻醉科, 221002; |
| |
| 摘 要： | 此文综述sugammade近年来的临床研究概况。文章认为sugammadex可安全有效拮抗罗库溴铵的肌松效应，其效能呈剂量依赖性。同时也可安全有效拮抗未成年人、老年人或心脏病患者、肺病患者和肾衰患者罗库溴铵的肌松效应，副作用少。与传统肌松拮抗药比较，sugammadex具有显著优势，有广泛应用前景。
|
| 关 键 词： | 肌松药拮抗剂 Sugammadex 罗库溴铵 |
Progress in clinical research of selective relaxant antognist,sugammadex |
| |
| Institution: | ZHOU Qiao-ling, YANG Cheng-xiang. (The Institute of Anesthesiology ＆ the Key Laboratory of Anesthesiology of Jiangsu Province, Xuzhou Medical College, Xuzhou 221002, China) |
| |
| Abstract: | Sugammadex can safely and effectively antagonize rocuronium-indnced neuromuscular blockade, in a dose-dependent manner, including the cases with pulmonary and cardiac diseases. The clinical use of sugammadex promises to eliminate many of the shortcomings in our current practice with regard to the antagonism of rocuronium and possibly other steroidal neuromuscular blockers. |
| |
| Keywords: | Selective relaxant antagonist Sugammadex Rocuronium |
| 本文献已被 维普 等数据库收录！ |
